The
sigma-2 receptor is expressed in higher density in proliferating (P)
tumor cells versus quiescent (Q)
tumor cells, thus providing an attractive target for imaging the proliferative status (i.e., P:Q ratio) of solid
tumors. Here we evaluate the utility of the
sigma-2 receptor ligand 2-(2-[(18)F]fluoroethoxy)-N-(4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl)-5-methyl-
benzamide, [(18)F]ISO-1, in two different rodent models of
breast cancer. In the first study, small animal Positron Emission Tomography (PET) imaging studies were conducted with [(18)F]ISO-1 and (18)FDG in xenografts of mouse mammary
tumor 66 and tracer uptake was correlated with the in vivo P:Q ratio determined by flow cytometric measures of
BrdU-labeled
tumor cells. The second model utilized a chemically-induced (
N-methyl-N-nitrosourea [MNU]) model of rat mammary
carcinoma to correlate measures of [(18)F]ISO-1 and FDG uptake with MR-based volumetric measures of
tumor growth. In addition, [(18)F]ISO-1 and FDG were used to assess the response of MNU-induced
tumors to
bexarotene and
Vorozole therapy. In the mouse mammary 66
tumors, a strong linear correlation was observed between the [(18)F]ISO-1
tumor: background ratio and the proliferative status (P:Q ratio) of the
tumor (R = 0.87). Similarly, measures of [(18)F]ISO-1 uptake in MNU-induced
tumors significantly correlated (R = 0.68, P<0.003) with changes in
tumor volume between consecutive MR imaging sessions. Our data suggest that PET studies of [(18)F]ISO-1 provide a measure of both the proliferative status and
tumor growth rate, which would be valuable in designing an appropriate treatment strategy.